Literature DB >> 16108842

Large-scale studies of the Leu72Met polymorphism of the ghrelin gene in relation to the metabolic syndrome and associated quantitative traits.

C Bing1, L Ambye, M Fenger, T Jørgensen, K Borch-Johnsen, S Madsbad, S A Urhammer.   

Abstract

AIM: Recently, low-frequency polymorphisms in the coding region of the ghrelin gene were suggested to be involved in the aetiology of obesity and to modulate glucose-induced insulin secretion in different ethnic study groups. The objective of the present large study was to investigate whether the Leu72Met polymorphism of the ghrelin gene associates with features of the metabolic syndrome (MS) in the Danish population.
METHODS: The variant was examined, using PCR-RFLP, in the DanMONICA cohort, a population-based sample of 2413 subjects. The metabolic syndrome was defined using the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) criteria.
RESULTS: The allelic frequency of the Met72 allele was 8.6%[6.3-10.9%] in the MS group and 7.8%[7.0-8.6%] among subjects classified as not having the MS (NS). Similarly, there were no significant differences across the three groups of genotypes with respect to any of the examined variables, including BMI, waist circumference, fasting serum lipids, plasma glucose, serum insulin and HOMA estimates of insulin resistance and insulin secretion.
CONCLUSION: In conclusion, the Leu72Met polymorphism of the ghrelin gene is not associated with the metabolic syndrome or related quantitative traits in the Danish population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16108842     DOI: 10.1111/j.1464-5491.2005.01575.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  8 in total

1.  Plasma ghrelin levels and polymorphisms of ghrelin gene in Chinese obese children and adolescents.

Authors:  J F Zhu; L Liang; C C Zou; J F Fu
Journal:  Ir J Med Sci       Date:  2010-06-02       Impact factor: 1.568

Review 2.  Metabolic syndrome and underlying genetic determinants-A systematic review.

Authors:  Sanjeev Rana; Shafat Ali; Hilal Ahmad Wani; Qazi Danish Mushtaq; Swarkar Sharma; Muneeb U Rehman
Journal:  J Diabetes Metab Disord       Date:  2022-03-03

3.  Polymorphisms of genes coding for ghrelin and its receptor in relation to colorectal cancer risk: a two-step gene-wide case-control study.

Authors:  Daniele Campa; Barbara Pardini; Alessio Naccarati; Ludmila Vodickova; Jan Novotny; Verena Steinke; Nils Rahner; Elke Holinski-Feder; Monika Morak; Hans K Schackert; Heike Görgens; Judith Kötting; Beate Betz; Matthias Kloor; Christoph Engel; Reinhard Büttner; Peter Propping; Asta Försti; Kari Hemminki; Roberto Barale; Pavel Vodicka; Federico Canzian
Journal:  BMC Gastroenterol       Date:  2010-09-28       Impact factor: 3.067

4.  Ghrelin in diabetes and metabolic syndrome.

Authors:  Leena Pulkkinen; Olavi Ukkola; Marjukka Kolehmainen; Matti Uusitupa
Journal:  Int J Pept       Date:  2010-04-27

5.  Recent advances in potential clinical application of ghrelin in obesity.

Authors:  Christine Delporte
Journal:  J Obes       Date:  2012-02-20

6.  Ghrelin Gene Variants Influence on Metabolic Syndrome Components in Aged Spanish Population.

Authors:  Mireia Mora; Victoria Adam; Elisabet Palomera; Sebastian Blesa; Gonzalo Díaz; Xavier Buquet; Mateu Serra-Prat; Juan Carlos Martín-Escudero; Ana Palanca; Javier Felipe Chaves; Manuel Puig-Domingo
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

7.  Ethnicity-Specific Association Between Ghrelin Leu72Met Polymorphism and Type 2 Diabetes Mellitus Susceptibility: An Updated Meta-Analysis.

Authors:  Rong Huang; Sai Tian; Rongrong Cai; Jie Sun; Yanjue Shen; Shaohua Wang
Journal:  Front Genet       Date:  2018-11-14       Impact factor: 4.599

8.  Leu72Met polymorphism of GHRL gene decreases susceptibility to type 2 diabetes mellitus in a Mexican population.

Authors:  Edgar Alfonso Rivera-León; Mara Anaís Llamas-Covarrubias; Sergio Sánchez-Enríquez; Erika Martínez-López; Mercedes González-Hita; Iris Monserrat Llamas-Covarrubias
Journal:  BMC Endocr Disord       Date:  2020-07-22       Impact factor: 2.763

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.